Goedert was awarded the Metlife Foundation Award for Medical Research in Alzheimer's Disease in 1996, the Potamkin Prize in 1998 and the European Grand Prix for Research by the Foundation for Research on Alzheimer's disease in 2014. In 2018 he was one of four recipients of the Grete Lundbeck European Brain Research Prize with the citation "For their groundbreaking research on the genetic and molecular basis of Alzheimer's disease, with far-reaching implications for the development of new therapeutic interventions as well as for the understanding of other neurodegenerative diseases of the brain".[2] In 2019 he received the Royal Medal.[3] and the Rainwater Charitable Foundation prize for outstanding innovation in neurodegenerative disorder research.[4]
Goedert's work combines biochemical, molecular biological and structural techniques to investigate common neurodegenerative diseases, including Alzheimer's and Parkinson's.[5] His research focused on the abnormal filamentous inclusions that characterise Parkinson's and Alzheimer's, showing that the intracellular filaments of these diseases are made of either alpha-synuclein or tau protein.[6] Goedert's team identified mutations in MAPT, the tau gene, that cause rare inherited forms of frontotemporal dementia with tau inclusions, establishing a central role for tau assembly in the disease.[7]
Works
Irene Litvan, ed. (2005). "Neurodegenerative α-Synucleinopathies". Atypical Parkinsonian disorders: clinical and research aspects. Springer. p. 77. ISBN978-1-58829-331-2.
References
^"Michel Goedert". Alzforum. 19 October 2008. Retrieved 20 December 2019.